Table 3.
Cancer type | Set | Stage | Age | Follow-up time (month) | Survival status | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | Mean ± SD | Range | Mean ± SD | Range | Alive | Dead | ||
BRCA | Trainingset | 70 | 224 | 105 | 11 | 56.98 ± 12.98 | 26–90 | 31.46 ± 35.58 | 0–197 | 174 | 369 |
Testing set | 68 | 228 | 106 | 11 | 57.08 ± 13.26 | 26–90 | 31.3 ± 37.32 | 0–238 | 168 | 361 | |
P value | 1a | 0.93b | 0.96b | 0.95a | |||||||
COAD | Trainingset | 29 | 67 | 52 | 28 | 64.84 ± 12.77 | 31–90 | 33.35 ± 32.72 | 1–151 | 40 | 115 |
Testing set | 27 | 61 | 46 | 25 | 64.86 ± 13.77 | 34–90 | 32.99 ± 27.68 | 2–143 | 40 | 115 | |
P value | 1a | 0.99b | 0.92b | 1a | |||||||
ESCA | Trainingset | 20 | 50 | 40 | 16 | 62.52 ± 11.48 | 42–86 | 17.81 ± 14.96 | 1–69 | 39 | 54 |
Testing set | 22 | 52 | 39 | 16 | 62.31 ± 12.32 | 27–90 | 17.96 ± 18.07 | 1–124 | 39 | 54 | |
P value | 0.99a | 0.91b | 0.95b | 1a | |||||||
LUAD | Trainingset | 129 | 57 | 41 | 12 | 65.1 ± 10.25 | 40–87 | 30.1 ± 30.96 | 1–236 | 86 | 151 |
Testing set | 126 | 60 | 37 | 13 | 65.16 ± 10.04 | 33–88 | 30.18 ± 30.13 | 1–242 | 86 | 148 | |
P value | 0.96a | 0.95b | 0.98b | 0.92a | |||||||
LUSC | Trainingset | 92 | 70 | 31 | 5 | 67.6 ± 8.87 | 44–90 | 33.21 ± 31.36 | 1–157 | 83 | 109 |
Testing set | 85 | 70 | 30 | 4 | 67.56 ± 8.6 | 40–85 | 32.87 ± 32.26 | 1–177 | 81 | 108 | |
P value | 0.98a | 0.96b | 0.92b | 1a | |||||||
PAAD | Trainingset | 11 | 77 | 3 | 4 | 64.73 ± 11.37 | 40–85 | 19.06 ± 14.41 | 1–77 | 50 | 43 |
Testing set | 12 | 76 | 4 | 4 | 64.84 ± 10.61 | 35–88 | 19.07 ± 16.96 | 1–92 | 50 | 43 | |
P value | 1a | 0.95b | 1b | 1a | |||||||
UCEC | Trainingset | 131 | 20 | 52 | 13 | 64.21 ± 11.33 | 33–90 | 33.31 ± 28.82 | 1–229 | 38 | 180 |
Testing set | 133 | 23 | 49 | 11 | 64.22 ± 11.08 | 31–90 | 33.2 ± 28.08 | 1–189 | 38 | 178 | |
P value | 0.92a | 1b | 0.97b | 1a |
aRepresents the p value calculated by Fisher’s exact test
bRepresents the p value calculated by T test